TY - JOUR
T1 - Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers
AU - Dickson, Dennis W.
AU - Baker, Matthew C.
AU - Jackson, Jazmyne L.
AU - Dejesus-Hernandez, Mariely
AU - Finch, Ni Cole A.
AU - Tian, Shulan
AU - Heckman, Michael G.
AU - Pottier, Cyril
AU - Gendron, Tania F.
AU - Murray, Melissa E.
AU - Ren, Yingxue
AU - Reddy, Joseph S.
AU - Graff-Radford, Neill R.
AU - Boeve, Bradley F.
AU - Petersen, Ronald C.
AU - Knopman, David S.
AU - Josephs, Keith A.
AU - Petrucelli, Leonard
AU - Oskarsson, Björn
AU - Sheppard, John W.
AU - Asmann, Yan W.
AU - Rademakers, Rosa
AU - Van Blitterswijk, Marka
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/10/8
Y1 - 2019/10/8
N2 - The majority of the clinico-pathological variability observed in patients harboring a repeat expansion in the C9orf72-SMCR8 complex subunit (C9orf72) remains unexplained. This expansion, which represents the most common genetic cause of frontotemporal lobar degeneration (FTLD) and motor neuron disease (MND), results in a loss of C9orf72 expression and the generation of RNA foci and dipeptide repeat (DPR) proteins. The C9orf72 protein itself plays a role in vesicular transport, serving as a guanine nucleotide exchange factor that regulates GTPases. To further elucidate the mechanisms underlying C9orf72-related diseases and to identify potential disease modifiers, we performed an extensive RNA sequencing study. We included individuals for whom frontal cortex tissue was available: FTLD and FTLD/MND patients with (n = 34) or without (n = 44) an expanded C9orf72 repeat as well as control subjects (n = 24). In total, 6706 genes were differentially expressed between these groups (false discovery rate [FDR] < 0.05). The top gene was C9orf72 (FDR = 1.41E-14), which was roughly two-fold lower in C9orf72 expansion carriers than in (disease) controls. Co-expression analysis revealed groups of correlated genes (modules) that were enriched for processes such as protein folding, RNA splicing, synaptic signaling, metabolism, and Golgi vesicle transport. Within our cohort of C9orf72 expansion carriers, machine learning uncovered interesting candidates associated with clinico-pathological features, including age at onset (vascular endothelial growth factor A [VEGFA]), C9orf72 expansion size (cyclin dependent kinase like 1 [CDKL1]), DPR protein levels (eukaryotic elongation factor 2 kinase [EEF2K]), and survival after onset (small G protein signaling modulator 3 [SGSM3]). Given the fact that we detected a module involved in vesicular transport in addition to a GTPase activator (SGSM3) as a potential modifier, our findings seem to suggest that the presence of a C9orf72 repeat expansion might hamper vesicular transport and that genes affecting this process may modify the phenotype of C9orf72-linked diseases.
AB - The majority of the clinico-pathological variability observed in patients harboring a repeat expansion in the C9orf72-SMCR8 complex subunit (C9orf72) remains unexplained. This expansion, which represents the most common genetic cause of frontotemporal lobar degeneration (FTLD) and motor neuron disease (MND), results in a loss of C9orf72 expression and the generation of RNA foci and dipeptide repeat (DPR) proteins. The C9orf72 protein itself plays a role in vesicular transport, serving as a guanine nucleotide exchange factor that regulates GTPases. To further elucidate the mechanisms underlying C9orf72-related diseases and to identify potential disease modifiers, we performed an extensive RNA sequencing study. We included individuals for whom frontal cortex tissue was available: FTLD and FTLD/MND patients with (n = 34) or without (n = 44) an expanded C9orf72 repeat as well as control subjects (n = 24). In total, 6706 genes were differentially expressed between these groups (false discovery rate [FDR] < 0.05). The top gene was C9orf72 (FDR = 1.41E-14), which was roughly two-fold lower in C9orf72 expansion carriers than in (disease) controls. Co-expression analysis revealed groups of correlated genes (modules) that were enriched for processes such as protein folding, RNA splicing, synaptic signaling, metabolism, and Golgi vesicle transport. Within our cohort of C9orf72 expansion carriers, machine learning uncovered interesting candidates associated with clinico-pathological features, including age at onset (vascular endothelial growth factor A [VEGFA]), C9orf72 expansion size (cyclin dependent kinase like 1 [CDKL1]), DPR protein levels (eukaryotic elongation factor 2 kinase [EEF2K]), and survival after onset (small G protein signaling modulator 3 [SGSM3]). Given the fact that we detected a module involved in vesicular transport in addition to a GTPase activator (SGSM3) as a potential modifier, our findings seem to suggest that the presence of a C9orf72 repeat expansion might hamper vesicular transport and that genes affecting this process may modify the phenotype of C9orf72-linked diseases.
KW - Amyotrophic lateral sclerosis
KW - C9orf72
KW - Frontotemporal dementia
KW - Frontotemporal lobar degeneration
KW - Machine learning
KW - Motor neuron disease
KW - Repeat expansion disorders
KW - RNA sequencing
KW - Transcriptomics
KW - Vesicular transport
UR - http://www.scopus.com/inward/record.url?scp=85073059280&partnerID=8YFLogxK
U2 - 10.1186/s40478-019-0797-0
DO - 10.1186/s40478-019-0797-0
M3 - Article
C2 - 31594549
AN - SCOPUS:85073059280
SN - 2051-5960
VL - 7
JO - Acta Neuropathologica Communications
JF - Acta Neuropathologica Communications
IS - 1
M1 - 150
ER -